After trading lower premarket on an extended FDA review for its Tysabri drug, Biogen Idec (BIIB)...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

After trading lower premarket on an extended FDA review for its Tysabri drug, Biogen Idec (BIIB) is up 5.3%, as investors choose to focus on positive trial data for the company's BG-12 drug for treating MS. Jefferies says it now has "increased confidence" BG-12 will be the leading front-line treatment for MS."